Slide 1: Leading in sustainability
Leading in sustainability 9 September 2020 Conference call and webcast for analysts, institutional investors and rating agencies Session is being recorded
Slide 2: Forward-looking statements disclaimer
Forward-looking statements disclaimer In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking sta
Slide 3: Speakers
Leif Johansson Non-Executive Chairman of the Board Speakers Katarina Ageborg Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden 3
Slide 4: Agenda
Agenda Commitment Governance Leadership Closing and Q&A 4 FOR INTERNAL USE ONLY
Slide 5: Commitment to sustainability
Commitment to sustainability 5
Slide 6: Why is sustainability so important now?
Why is sustainability so important now? The World Health In some high-income Plastic waste is found The World Economic Organization estimates countries, cancer in the guts of more Forum predicts that it that air pollution kills survival rates for than 90% of the will take more than 7 million people
Slide 7: AstraZeneca's commitment to sustainability
AstraZeneca’s commitment to sustainability Healthy people We use our capabilities to make the most Healthy meaningful impact where society needs it planet — health. We believe there is a strong connection between the health of our patients, our business, our workforce, our communities and the planet
Slide 8: Governance of sustainability
Governance of sustainability 8
Slide 9: Governance
Governance Board of Directors • Non-Executive Director Geneviève Berger oversees sustainability matters on behalf of the Board Senior Executive Team (SET) • Accountable for specific sustainability initiatives and review of the sustainability scorecard each quarter. • SET Sustainability rep: Katarina
Slide 10: We have well defined priorities
We have well defined priorities Access to Healthcare Environmental Protection Ethics and Transparency Health is at the heart The health of the planet Healthy societies promote of our business impacts all life equality and prosperity for all Our Address the global burden of NCDs Manage our environmen
Slide 11: Leadership in sustainability
Leadership in sustainability 11
Slide 12: We can all make an impact
We can all make an impact At AstraZeneca, we all work to make the world a better place. We push the boundaries of science to deliver life- changing medicines to the people who need them. Our focus on sustainability is integral to our efforts, and we continue to make advancements across our three pri
Slide 13: Our United Nations SDG impact
Our United Nations SDG impact Access to Healthcare Environmental Protection Ethics and Transparency Health is at the heart The health of the planet Healthy societies promote of our business impacts all life equality and prosperity for all SDG 3 – SDG 12 – SDG 5 – Good health and Responsible consumpt
Slide 14: Access to healthcare
Access to healthcare 14
Slide 15: Access to Healthcare
Access to Healthcare Our focus areas We have Health is at a bold ambition: the heart of Disease prevention and treatment our business Work towards a future where all people have access to sustainable Responsible R&D healthcare solutions for life-changing Investments in health systems treatment and p
Slide 16: Access to healthcare – impact
Access to healthcare – impact 81,000+ 19.8m+ 9.7m+ UNGC healthcare workers reached reached through Patient Patron sponsor of trained (cumulative) through access Assistance Programmes Business Ambition for programmes (cumulative) Climate and Health (cumulative) 16 Source: AstraZeneca Sustainability R
Slide 17: Environmental protection
Environmental protection 17
Slide 18: Environmental protection
Environmental protection Our focus areas We have The health a bold ambition: of the planet Product environmental stewardship impacts all life Manage our environmental impact across all our activities Pharmaceuticals in the environment and our products, working toward Greenhouse gas reduction a resto
Slide 19: Environmental protection – impact
Environmental protection – impact Zero 11% 11% 62% 18% 97% carbon reduction increase in our of our reduction in of API emission in Scope 1 waste electricity is our water use discharges from commitment emissions renewable direct suppliers by 2025 (sites demonstrated and fleet) as safe 19 Source: Astr
Slide 20: Ethics and transparency
Ethics and transparency 20
Slide 21: Ethics and transparency
Ethics and transparency Our focus areas Equality and prosperity We have for all, fosters Ethical business culture a bold ambition: healthy Create positive societal Inclusion and diversity societies impact and promote ethical behaviour in all Talent and workforce evolution markets across our value ch
Slide 22: Ethics and transparency – impact
Ethics and transparency – impact 45.4% 63.3 86% 96 89 women in instances of non- feel that countries disclosing manufacturing management compliance with the AstraZeneca is data points on partners were roles Code of Ethics per a Great Place Sustainability evaluated 1,000 employees to Work Transparenc
Slide 23: Q&A panel
Q&A panel Ashling Mulvaney Head of Access to Healthcare Leif Johansson Non-Executive Chairman of the Board Jason Snape Head of Environmental Protection Katarina Ageborg Executive Vice-President, Sustainability and Chief Compliance Heather Stewart Officer; President AstraZeneca AB, Sweden Head of Eth
Slide 24: Questions & Answers
Questions & Answers 24
Slide 25: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl